Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD‐L1

Abstract Despite their potent antitumor activity, clinical application of immune checkpoint inhibitors has been significantly limited by their poor response rates (<30%) in cancer patients, primarily due to immunosuppressive tumor microenvironments. As a representative immune escape mechanism, cance...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jung Min Shin, Chan‐Hyeong Lee, Soyoung Son, Chan Ho Kim, Jae Ah Lee, Hyewon Ko, Sol Shin, Seok Ho Song, Seong‐Sik Park, Ju‐Hyun Bae, Ju‐Mi Park, Eun‐Ji Choe, Moon‐Chang Baek, Jae Hyung Park
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2022-02-01
Col·lecció:	Advanced Science
Matèries:	combination therapy exosomal PD‐L1 exosome immune checkpoint therapy immune escape tumor microenvironment
Accés en línia:	https://doi.org/10.1002/advs.202103245
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!